Skip to main content

SARS-CoV-2 nsp14 Antibody [Allophycocyanin]

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-07054APC

Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

SARS-CoV-2

Applications

ELISA

Label

Allophycocyanin (Excitation = 620-650 nm, Emission = 660-670 nm)

Antibody Source

Polyclonal Rabbit IgG

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Specifications

Immunogen

This antibody was raised against a peptide corresponding to 14 amino acids near the center of SARS-CoV-2 (COVID-19) NSP14 (ExoN) protein. The immunogen is located between 30-80 amino acids of SARS-CoV-2 (COVID-19) NSP14 (ExoN).

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Applications for SARS-CoV-2 nsp14 Antibody [Allophycocyanin]

Application
Recommended Usage

ELISA

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Peptide affinity purified

Formulation

PBS

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: SARS-CoV-2 nsp14

SARS-CoV-2 Nonstructural Protein 14 (NSP14) is one of the sixteen nonstructural proteins of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19 (1). SARS-CoV-2 NSP14 is 527 amino acids (aa) with a theoretical molecular weight of 59.8 kDa (1-3). The amino acid sequence alignment of SARS-CoV and SARS-CoV-2's NSP14 has 95.1% sequence identity and 99.1% sequence similarity (1). Functionally, NSP14 has both 3'-5' exoribonuclease activity and N7-methyltransferase activity (1-4). The N-terminal domain of NSP14 has exoribonuclease activity (ExoN) with three conserved motifs (DE, E, and D) and belongs to the DEDD superfamily (3,4). NSP14 ExoN activity has a role in RNA proofreading during viral replication (3,4). NSP10 has been shown to interact with the exoribonuclease domain of NSP14, increasing its activity (3,4). On the other hand, the carboxyl-terminal of NSP14 has the N7-methyltransferase activity and functions in viral mRNA capping (3,4).

References

1. Yoshimoto F. K. (2020). The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. The Protein Journal. https://doi.org/10.1007/s10930-020-09901-4

2. Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O'Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., Tummino, T. A., Huttenhain, R., Kaake, R. M., Richards, A. L., Tutuncuoglu, B., Foussard, H., Batra, J., Haas, K., Modak, M., Kim, M., ... Krogan, N. J. (2020). A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. https://doi.org/10.1038/s41586-020-2286-9

3. Qiu, Y., & Xu, K. (2020). Functional studies of the coronavirus nonstructural proteins. STEMedicine. https://doi.org/10.37175/stemedicine.v1i2.39

4. Romano, M., Ruggiero, A., Squeglia, F., Maga, G., & Berisio, R. (2020). A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping. Cells. https://doi.org/10.3390/cells9051267

Alternate Names

ExoN, Guanine-N7 methyltransferase, Non-structural protein 14, nsp14, Proofreading exoribonuclease

Gene Symbol

ORF1ab

Additional SARS-CoV-2 nsp14 Products

Product Documents for SARS-CoV-2 nsp14 Antibody [Allophycocyanin]

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for SARS-CoV-2 nsp14 Antibody [Allophycocyanin]

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...